Antimalarial medicines and molecules geared towards the needs of children

20 Nov 2020

A child dies from malaria every 2 minutes – the vast majority from Africa. To help reduce this burden, MMV has built the richest malaria drug pipeline in history, with 13 new antimalarials now treating patients. These medicines have contributed to saving more than 2.2 million lives and are helping bend the curve towards the eradication of malaria. To mark World Children’s Day 2020, we are proud to present the antimalarials MMV and partners have developed for children, as well as the projects we are working on for the future. 

  • Photo credits:

    Slide 1: Novartis; Slide 2: Anna Wang; Slide 3: Anna Wang; Slide 4: Maud Majeres Lugand/MMV; Slide 5: Maud Majeres Lugand/MMV; Slide 6: Anna Wang; Slide 7: Alena Koscalove/MSF; Slide 8: Amevi Wisdom/Unsplash


    1.Tafenoquine is marketed as Kozenisin Australia and Krintafel in the USA. Trademarks are owned or licensed to the GSK group of companies. 

    2. Tafenoquine Exposure Assessment in Children.
     

    3. World Health Organization.  Seasonal malaria chemoprevention (Last updated: 1 May 2017): http://www.who.int/malaria/areas/preventive_therapies/children/en/index.html 

    4. Druetz T. “Evaluation of direct and indirect effects of seasonal malaria chemoprevention in Mali".  Sci Rep 8, 8104 (2018). 

    5. Druetz T et al. “Impact Evaluation of Seasonal Malaria Chemoprevention Under Routine Program Implementation: A Quasi-Experimental Study in Burkina Faso.” Am J Trop Med Hyg. 98 (2): 524-533 (2018). 

    6. SEAsonal MAlaria Chemoprevention Extension.